Autosomal recessive cerebellar ataxias and autosomal recessive hereditary spastic paraplegias are clinically and genetically heterogeneous disorders with diverse neurological and non-neurological features. We herein describe a Japanese patient with a slowly progressive form of ataxia and spastic paraplegia. Using whole exome sequencing, we identified a novel homozygous frameshift mutation in SPG7, encoding paraplegin, in this patient. This is the first report of an SPG7 mutation in the Japanese population. For disorders previously undetected in a particular population, or unrecognized/atypical phenotypes, exome sequencing may facilitate molecular diagnosis.
Introduction
Hereditary ataxias and hereditary spastic paraplegias (HSPs) are clinically and genetically heterogeneous neurological disorders exhibiting an autosomal dominant, autosomal recessive or X-linked mode of inheritance. Mutations in more than 30 different genes have been identified for autosomal recessive cerebellar ataxias (ARCAs) (1-3), and mutations in over 22 different genes have been identified for autosomal recessive hereditary spastic paraplegias (ARHSPs) (4) (5) (6) . Both disorders are generally associated with diverse neurological and non-neurological symptoms that partially overlap, resulting in complex phenotypes. Furthermore, while these disorders can be caused by mutations in the same gene, the phenotypes can vary. Therefore, genetic diagnostic tests for ARCAs and ARHSPs are complex and time-consuming. In this study, we describe a Japanese patient exhibiting a slowly progressive form of spastic ataxia. Using whole exome sequencing, we identified a causative mutation in SPG7 that has not been previously detected in the Japanese population.
Case Report
Clinical information and a blood sample were obtained from the patient after he provided his written informed consent. The experimental protocols were approved by the Institutional Review Board of Yokohama City University School of Medicine. Among the children of first-cousin parents, two were affected (including the proband), while two were healthy ( Figure A) . DNA was available from the proband only, who is now 64 years old. Arrhythmic episodes commenced at 6 years of age. At 34 years of age, he experienced stiffness in the legs after protracted periods in the cold and stumbled when moving swiftly. At -40 years of age, he felt stiffness in the legs after walking 5 kilometers and had difficulty moving briskly. At 47 years of age, he was examined in the hospital where he was diagnosed with a complicated form of HSP. At 49 years of age, he displayed slurred speech. These symptoms gradually worsened, and, at 54 years of age, he started using a cane when walking. He was admitted to our hospital for a clinical evaluation. He exhibited a disturbance of smooth pursuit eye movements as well as mild omnidirectional gaze palsy, dysarthria, pronounced spasticity and mild weakness of the lower extremities, extensor plantar reflexes (Babinski sign) and truncal instability. While the patellar tendon reflexes and Achilles tendon reflexes were increased, no knee or ankle clonus were observed. No pes cavus, muscle atrophy, fasciculation, involuntary movements, autonomic involvement or sensory involvement were observed. The patient exhibited slight cognitive decline. His score on a revised version of the Hasegawa Dementia Scale (HDS) was 24/30. The frontal assessment battery score was 13/18, indicating slight frontal lobe dysfunction. Laboratory biochemistry results were normal, including the levels of serum albumin, vitamin E and very long chain fatty acids. A nerve conduction study disclosed no neuropathy, and an ophthalmic evaluation revealed no ocular atrophy. Brain magnetic resonance imaging revealed moderate atrophy of the cerebellar hemispheres; however, no hypoplasia/atrophy of the corpus callosum, brain stem or cerebral cortex was observed ( Figure B ). The patient was diagnosed with ARCA, taking into consideration the dysarthria and cerebellar atrophy.
The patient was 64 years old at the last examination. He displayed moderate omnidirectional gaze palsy, impaired vertical and horizontal optokinetic nystagmus and slow saccade. Mild limb ataxia was also observed. Muscle weakness of the lower extremities was advanced, especially in the hamstrings and anterior tibial muscles (manual muscle testing 2-3), consistent with disturbance of the pyramidal tracts. He was unable to walk without holding on to something due to spasticity and muscle weakness. His cognitive impairment did not progress (HDS 22/30, Mini-Mental State Examination 26/30).
Exome sequencing
To identify the causative mutation, whole exome sequencing was performed on the patient's DNA. Genomic DNA was processed using a SureSelect Human All Exon Kit (50 Mb; Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. Captured DNAs were sequenced using a GAIIx sequencer (Illumina, San Diego, CA). Approximately 44.9 million paired-reads were mapped to the human reference genome. A coverage analysis revealed that 88.9% of the bases within the target regions were covered by 10 reads or more. We checked whether mutations were present in known ARCA or ARHSP genes. For 36/59 of the relevant genes, more than 90% of the entire coding sequence was covered by 10 reads or more (Table). A homozygous frameshift mutation, c.1342dup (NM_ 003119.2; p.His448Profs * 12), was identified in exon 10 of SPG7 (16q24.3, MIM 602783). Sanger sequencing on an ABI 3500xL (Life Technologies, Carlsbad, CA) confirmed c.1342dup homozygosity in the patient ( Figure C) . No mutations were detected using Sanger sequencing in the other exons of SPG7. The mutation was undetected in 752 control alleles. No other mutations located in exons or splice sites were detected among the 59 relevant genes.
Discussion
In this report, we described a case of an adult-onset slowly progressive form of spastic ataxia. Using whole exome sequencing, we were able to identify a novel homozygous frameshift mutation, c. 1342 dup (p.His448Profs * 12) in SPG7. SPG7 was the first gene identified in ARHSP (7). Mutations in SPG7 are known to cause both pure and complicated HSP phenotypes. In complicated forms, the clinical symptoms can be accompanied by cerebellar syndrome, optic neuropathy, supranuclear palsy and cognitive impairments (8) (9) (10) . Although mutations in SPG7 account for just under 5% of ARHSP cases in Europe (11), they have never been found in a Japanese population.
SPG7 encodes paraplegin, a nuclear DNA-encoded mitochondrial metalloprotease belonging to the adenosine triphosphatases associated with diverse cellular activities (AAA) family of proteins. Loss of the function of paraplegin leads to mitochondrial dysfunction. The p.His448Profs * 12 mutation is predicted to result in a premature stop codon. Previous reports (7, (9) (10) (11) (12) (13) (14) (15) have revealed that missense and nonsense mutations located closer to the C-terminal of paraplegin than the p.His448Profs * 12 mutation can cause disease ( Figure D) . Recently, genotype-phenotype correlations were identified for SPG7: an association between cerebellar ataxia and SPG7 null alleles leading to an absence of protein products or severely truncated protein products and an association between optic nerve atrophy and a missense mutation in exon 10 (pArg470Gln) (9) . The clinical phenotype observed in our patient, who had cerebellar ataxia without optic nerve atrophy, is compatible with an SPG7 mutation. We concluded that the homozygous p.His448Profs * 12 mutation was deleterious and causative of the patient's clinical phenotype.
Because there are regional differences in the prevalence of recessive disorders, it is difficult to perform genetic testing for rare and heterogeneous disorders, especially when they have not been previously reported in the population. The relative frequencies of ARCAs and HSPs in patients with spinocerebellar ataxia spectrum disorders (including sporadic and hereditary cases) are estimated to be 1.8% and 4.7%, respectively (16) . Although the precise prevalence of each subtype of ARCA and ARHSP remains unknown, the relatively common ARCAs and ARHSPs observed in Japan are ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia/ataxia-oculomotor apraxia 1 (MIM 208920), ataxiaoculomotor apraxia 2 (MIM 606002), ataxia with isolated vitamin E deficiency (MIM 277460), ataxia-telangiectasia (MIM 208900), spastic ataxia, Charlevoix-Saguenay type (MIM 270550) and spastic paraplegia 11 ( MIM 604360) (17) . The clinical phenotype of our patient was not fully consistent with ARCA/ARHSPs previously reported in Japan. Considering the clinical and genetic diversity among ARCA/ARHSPs, we selected whole exome sequencing as the diagnostic method. Friedreich ataxia 1 (MIM 229300), which is primarily caused by the expansion of a trinucleotide repeat in FXN, may be undetectable by exome sequencing. However, an FXN mutation has never been described in the Japanese population, even though the gene has been tested for in suspected cases. In these cases, whole exome sequencing is the most promising method for identifying a causative mutation in one of the known ARCA or ARHSP genes. Indeed, most ARCA and ARHSP genes were covered by our exome sequencing approach, with the exception of the few genes that had low read-coverage, such as KIAA0415 and GJC2 (Table) . More recently, the readcoverage was improved by upgrading the bait design ( Table) .
Recently, it became feasible to use whole exome sequencing for diagnostic purposes. Even for disorders previously undetected in a particular population, or unrecognized/atypical phenotypes, exome sequencing may facilitate molecular diagnosis (18, 19) . In our case, the diagnosis varied, depending on whether the clinicians emphasized pyramidal or cerebellar signs. We believe that a diagnosis provided by The percentage of coding sequence covered by 10 or more reads. The 50Mb column shows data for our patient; the 51 Mb column shows reference data from 4 patients with other diseases and whose DNA was processed using the latest version of SureSelect Human All Exon Kit. Genes with > 90% of the total coding sequence covered by 10 or more reads are highlighted in bold.
exome sequencing would improve the quality of clinical evaluation in patients with rare diseases.
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